The treatment of uterine bleeding with vasopressin hormonogen (glypressin)--a pilot study.
In a pilot study 12 women with severe uterine bleeding received an intravenous injection of 0.2 mg of a vasopressin hormonogen, glypressin. In 11 of the patients a rapid reduction or cessation of blood loss were observed. Two patients had facial pallor following the injection but no other side effects occurred. Five of the older women with long histories of menorrhagia were placed on a regime of one injection of glypressin on the first day of menstruation for six months; in all of them the duration of bleeding was reduced to three days and the monthly blood loss became very slight. On the basis of these results more extensive clinical trials in menorrhagia and metrorrhagia are recommended.
D000293:Adolescent; D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects; D002648:Child; D005260:Female; D006801:Humans; D008236:Lypressin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008595:Menorrhagia / Q000188:drug therapy; D008875:Middle Aged; D014592:Uterine Hemorrhage / Q000188:drug therapy* / Q000209:etiology
D008236:Lypressin